MEDIA

AMS BioteQ showcased its SeepPlug™ growing medium at Taiwan Smart Agriweek 2026, highlighting cultivation trials from Taiwan, Japan, and Vietnam. The company also debuted the “Sprouting Lucky Cat,” extending its agricultural technology into home gardening and everyday life.

Wound dressing changes are often one of the most painful moments for patients. Traditional gauze dressings tend to adhere to newly formed tissue upon removal, frequently causing trauma, severe pain, and delayed healing.

To meet the demand for high-quality wound care products in the Japanese market, AMS BioteQ (Stock Code: 6864-TW) has continued to deepen its overseas medical device strategy.

AMS BioteQ participated in the prestigious INTERPHEX WEEK TOKYO 2025, held from July 9 to 11, 2025, in Tokyo, Japan.

Rooted in Taiwan, Global in Vision: AMS BioteQ (6864) Pioneers Asian Market Entry with Medical Innovations.

In the medical field, wound healing has always been a subject of significant concern. The wound healing process is not only slow and complex but also requires proper care to prevent infection, alleviate pain, and minimize scar formation. To support wound healing, dressings are widely used as they protect the wound, absorb exudate, and maintain a moist environment.

With the return of former U.S. President Trump and the implementation of a new wave of trade protectionist policies, global supply chains are once again facing turbulence. The U.S. recently announced a 10% basic tariff on all imported goods, with higher rates imposed on certain high-sensitivity products and specific countries.

AMS BioteQ (6864-TW) Teams Up with Middle Eastern Partners to Introduce SIPSIP® Dressings to the Region!

AMS BioteQ (6864-TW) has sparked widespread attention with its innovative product, SeepPlug, unveiled at the 2025 Taiwan International Orchid Show. Developed using medical material technology, SeepPlug embodies three core values: fully degradable substrate structure, exclusive pore regulation technology, and enhanced stress resistance.

In November 2024, AMS BioteQ made its debut at one of the world’s largest medical exhibitions, MEDICA 2024 in Düsseldorf, Germany, while also laying the groundwork for its upcoming participation in Arab Health 2025 in Dubai, UAE.

AMS BioteQ, founded by Dr. George Tsai in 2018, focuses on drug development and innovative medical materials research. The company leverages Taiwan’s unique natural resources and has successfully expanded into the global anti-infection market.

AMS BioteQ (stock code: 6864) is making waves in Japan with its innovative technologies and flexible production capabilities.